Benign neoplasm: Endocrine gland, other/unspecified

CD2_BENIGN_ENDOCRINE_NOS

sebaceous adenocarcinoma: An adenocarcinoma with sebaceous differentiation. It presents as a painless mass and it may be multifocal. It grows in the ocular adnexae and in the skin of head and neck, trunk, genitals, and extremities. It is characterized by the presence of malignant cells with multivesicular and clear cytoplasm. It may recur and metastasize.

Endpoint definition

↥

FinnGen phenotype data

321302 individuals

Apply sex-specific rule None

321302

Check conditions None

321302

Filter registries

Hospital Discharge: ICD-10 D35.7&, D35.9&

Hospital discharge: ICD-9 227[8-9]

Hospital discharge: ICD-8 226[8-9]

Cause of death: ICD-10 D35.7&, D35.9&

Cause of death: ICD-9 227[8-9]

Cause of death: ICD-8 226[8-9]

Check pre-conditions, main-only, mode, ICD version

Look only at ICD versions H.D: 10, 8, 9 ; C.O.D: 10, 8, 9

Check minimum number of events None

Include endpoints None

CD2_BENIGN_ENDOCRINE_NOS

Extra metadata

Level in the ICD hierarchy 3

First used in FinnGen datafreeze DF2

Similar endpoints

↥

List of similar endpoints to Benign neoplasm: Endocrine gland, other/unspecified based on the number of shared cases.

Broader endpoints:

Narrower endpoints:

None

Show all endpoint correlations

Summary Statistics

↥

Key figures

	All	Female	Male
Number of individuals	70	49	21
Unadjusted prevalence (%)	0.02	0.03	0.02
Mean age at first event (years)	45.27	44.05	48.10

Mortality

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	-	-	-	-
15 years	-	-	-	-
5 years	-	-	-	-
1 year	-	-	-	-

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: CD2_BENIGN_ENDOCRINE_NOS – Benign neoplasm: Endocrine gland, other/unspecified
GWS hits:

Survival analyses between endpoints

↥

Plot

before Benign neoplasm: Endocrine gland, other/unspecified
after Benign neoplasm: Endocrine gland, other/unspecified

Loading survival analyses plot

Table

Loading survival analyses table

Drugs most likely to be purchased after Benign neoplasm: Endocrine gland, other/unspecified

↥